A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women

Fertility and Sterility

Volumn 77, Issue 5, 2002, Pages 945-951

  Prelevic, Gordana M ^a,b   Kwong, Pandina ^a   Byrne, Dominic J ^a   Jagroop, I Anita ^a   Ginsburg, Jean ^a   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

C reactive protein; Cardiovascular risk; Conjugated equine E; Glycated hemoglobin; Hormone replacement therapy; Tibolone; Transdermal E2

Indexed keywords

ANTIOXIDANT; C REACTIVE PROTEIN; CHOLESTEROL; CONJUGATED ESTROGEN; ENDOTHELIN 1; ESTRACOMBI; ESTRADIOL; FIBRINOGEN; GESTAGEN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREMPACKC; TIBOLONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; AGED; ANTIOXIDANTS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; ENDOTHELIN-1; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LIPIDS; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; RISK FACTORS;

EID: 0036253286     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(02)03078-9     Document Type: Article

References (47)

1. Cardiovascular health and disease in women
2. Non-contraceptive estrogen use and risk of cardiovascular disease: An overview and critique of the literature
3. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
4. Postmenopausal estrogen use and occlusion of coronary arteries
5. Postmenopausal estrogen use and coronary atherosclerosis
6. Estrogen-induced uterine vasodilatation is antagonized by L-nitroarginine methyl ester, an inhibitor of nitric oxide synthesis
7. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal
8. 17Beta estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease
9. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors
10. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
11. Postmenopusal hormones and recurrence of coronary events in the Nurses' Health Study
12. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
13. The EWA (Estrogen in Women with Atherosclerosis) study: A randomised study of the use of hormone replacement therapy in women with angiographically verified coronary artery disease
14. The place of tibolone in menopausal therapy
15. A two year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin
16. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein (a): A randomized study
17. Effects of tibolone on lipoprotein(a) and HDL subfractions
18. A two year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins A1 and B
19. Cardiovascular mortality and non-contraceptive estrogen use in women: Results from the Lipid Research Clinics Program Follow-up Study
20. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: Response to ciprofibrate or lifestyle advice
21. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
22. Lipoprotein(a) immunoassays: Comparison of a semi-quantitative latex method and two monoclonal enzyme immunoassays
23. Reference interval for serum C-reactive protein in healthy blood donors using the Dade Behring N Latex CRP mono assay
24. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates
25. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs
26. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project
27. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
28. The renaissance of C reactive protein
29. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening
30. C-reactive protein as a cardiovascular risk factor: More than epiphenomenon?
31. C-reactive protein, cardiovascular risk factors and mortality in a prostective study in the elderly
32. Effects of postmenopausal hormone on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Intervention (PEPI) study
33. Hormone replacement therapy and increased plasma concentrations of C-reactive protein
34. The effects of raloxifene compared with hormone replacement therapy on homocysteine and C-reactive protein in healthy postmenopausal women: A randomized controlled trial
35. Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein and C-reactive protein
36. Comparison of the anti-atherosclerotic effect of tibolone with that of estradiol and ethynil estradiol in cholesterol-fed, ovariectomized rabbits
37. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes
38. Hormone replacement therapy and glucose tolerance in EPIC-Norfolk: A population-based study
39. Short-term estrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM
40. Cardiovascular effects of ORG OD 14 - A new steroid therapy for climacteric symptoms
41. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: Effects on serum lipids and lipoproteins
42. Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population
43. Lipoprotein (a) levels in the Japanese population: Influence of age and sex, and relation to atherosclerotic risk factors
44. Lipoprotein (a) levels and isoforms and fibrinolytic activity in postmenopause - Influence of hormone replacement therapy
45. Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women
46. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Intervention (PEPI) trial
47. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin and thromboxane